Anthem Biosciences IPO: Check IPO Date, Live Subscription and Key Details
Anthem Biosciences is a technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) for drug discovery, development and manufacturing. It offers comprehensive CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles. The company also manufactures and sells Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. As of March 31, 2024, the company had 550 customers in over 44 countries.
Price Range
₹540.00-570.00
Issue Size
₹3,395 Cr
Lot Size
26 shares
IPO Type
Mainboard
GMP
₹179(+31.40%)
Est. Listing Price
₹749
Estimate Profit
₹4,654
Retail Portion
-
Key Metrics
Check Live GMPGMPFace Value
₹2
EPS
8.07
P/E Ratio
70.62
RoNW
20.8%
ROE
20.82%
Debt to Equity
0.05
Advertisement
Timeline
IPO Opens
14 Jul
IPO Closes
16 Jul
Allotment
17 Jul
Listing
21 Jul
IPO Timeline & Listing Details
| Event | Date | Details |
|---|---|---|
| IPO Open Date | 14 July 2025 | Subscription starts |
| IPO Close Date | 16 July 2025 | Subscription ends |
| Allotment Date | 17 July 2025 | Allotment |
| Listing Date | 21 July 2025 | Listing |
Investment Categories
| Category | Lots | Amount |
|---|---|---|
Retail (Min) | 1 | ₹14,820 |
Retail (Max)Just less than ₹2,00,000 | 13 | ₹1,92,660 |
SHNI (Min)Just above ₹2,00,000 | 14 | ₹2,07,480 |
SHNI (Max)Below ₹10,00,000 | 67 | ₹9,92,940 |
BHNIAbove ₹10,00,000 | 68 | ₹10,07,760 |
IPO Objectives
- The Company will not receive any proceeds from the Offer as it is a 100% Offer for Sale. All proceeds will go to the selling shareholders after deductions for offer-related expenses and taxes.
Strengths
- Fastest-growing CRDMO with broad service offerings for small molecules and biologics.
- Innovation-focused with advanced technological solutions across various drug development areas.
- Differentiated business model catering to small pharmaceutical and emerging biotech companies.
- Long-standing relationships with a large and diverse customer base.
- Wide specialty ingredients portfolio, well-positioned for market opportunities.
- Automated manufacturing infrastructure with a strong regulatory compliance record.
Weaknesses
- The entire IPO is an Offer for Sale, meaning the company will not receive any proceeds.
- High revenue concentration: Top 5 customers contributed ~71% of revenue in FY25, and over 55% of revenue comes from Europe.
- Manufacturing facilities are concentrated in Karnataka, posing regional risks.
- Vulnerable to rapid technological changes and evolving industry standards, requiring continuous investment.
Advertisement
Financial Performance
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹ Cr.) | 2,807.58 | 2,398.11 | 2,014.46 |
| Revenue (₹ Cr.) | 1,930.29 | 1,483.07 | 1,133.99 |
| PAT (₹ Cr.) | 451.26 | 367.31 | 385.19 |
| Net Worth (₹ Cr.) | 2,409.86 | 1,924.66 | 1,740.67 |
Peer Comparison
| Company | P/B Ratio | P/E Ratio | RONW (%) | Net Worth (₹ Cr.) |
|---|---|---|---|---|
| Anthem Biosciences Limited | 13.23 | 70.62 | 20.82% | 2,409.86 |
| Syngene International Ltd | 5.46 | 52.08 | 10.5% | 4,727 |
| Sai Life Sciences Limited | 8.07 | 100.98 | 7.99% | 975 |
Subscription Details
Daily Bids Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | 0.39x | 0.62x | 192.8x |
| NII | 1.64x | 10.26x | 44.69x |
| S-HNI | 2.02x | 9.93x | 30.76x |
| B-HNI | 1.44x | 10.42x | 51.66x |
| RII | 0.62x | 2.21x | 5.92x |
| EMP | 1.04x | 2.74x | 6.89x |
| Total | 0.77x | 3.48x | 67.39x |
Overall Subscription Statistics
| Category | Shares Offered | Shares Bid | Bid Amount (₹ Cr) |
|---|---|---|---|
| QIB | 1,18,83,334 | 2,29,10,95,976 | 1,30,592.47 |
| NII | 89,12,500 | 39,83,06,792 | 22,703.49 |
| Small NII | 29,70,833 | 9,13,88,258 | 5,209.13 |
| Big NII | 59,41,667 | 30,69,18,534 | 17,494.36 |
| RII | 2,07,95,833 | 12,32,07,422 | 7,022.82 |
| EMP | 1,58,654 | 10,93,274 | 62.32 |
| Total | 4,17,50,321 | 2,81,37,03,464 | 1,60,381.1 |
Advertisement
Company Details
- Anthem Biosciences Ltd.
- No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka-560099, India
- +91 080 6672 400
- investors.abl@anthembio.com
- https://www.anthembio.com/
Registrar Details
- Kfin Technologies Limited
- 04067162222, 04079611000
- anthem.ipo@kfintech.com
- https://kosmic.kfintech.com/ipostatus/
Loading comments...